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Screening for coronary artery disease (CAD) in hemodialysis
patients is hampered by contraindications and/or limitations
of the available techniques in this population. Myocardial
perfusion scintigraphy (MPS) using dipyridamole has been
considered inaccurate due to abnormally high basal levels of
adenosine in uremia that could blunt the vasodilatory
response. Since dobutamine may be more reliable, we
directly compared the two in patients on hemodialysis. We
performed MPS at rest and after separate dipyridamole or
dobutamine stress in 121 chronic hemodialysis patients.
More numerous, larger, and more intense reversible lesions
were induced with dobutamine than with dipyridamole,
mainly in the anteroseptal segments. Reversibility with
dipyridamole but not dobutamine MPS was independently
and strongly related with mortality associated with CAD and
with fatal and non-fatal CAD. We hypothesize that the
chronotropic action of dobutamine induced alterations of
wall motion, leading to spurious perfusion defects, not unlike
artifacts seen with left bundle branch block. Our study shows
that even though dobutamine induced more pronounced
myocardial ischemia than dipyridamole in chronic
hemodialysis patients, dipyridamole MPS more accurately
identifies patients at high risk for subsequent cardiac death
or non-fatal CAD than dobutamine.
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Two recent observations rekindle the pursuit of the optimal
coronary artery disease (CAD)-screening technique in chronic
hemodialysis patients. First, the prevalence of asymptomatic
CAD in hemodialysis patients seems to rise, commensurate
with the increasing age and prevalence of diabetes in the hemo-
dialysis population. In 1984, Rostand et al.1 reported that
10% of asymptomatic dialysis patients had significant CAD, a
prevalence not so different from that in the general popula-
tion. In 2005, Ohtake et al.2 performed a coronary angiogra-
phy at the initiation of dialysis in 30 asymptomatic patients
without cardiac history. Significant lesions were present in
53% of the population and in 83% of the patients with dia-
betes. In another report, significant CAD was present in 54%
(7 of 13) of asymptomatic patients, just before initiation of
dialysis.3 Conversely, 75% of diabetic hemodialysis patients
with angiographically documented CAD were asymptomatic.4
Second, coronary revascularization improves long-term
prognosis in hemodialysis patients. In 1992, Manske et al.5
had already shown that coronary revascularization, either by
coronary artery bypass grafting (CABG) or by percutaneous
coronary intervention (PCI), reduced cardiac morbidity and
mortality in asymptomatic renal transplant candidates with
diabetes and with at least one coronary artery stenosis greater
than 75%, when compared with medical therapy alone. This
observation was recently extended to the hemodialysis
population in general. In a prospective cohort study of 259
hemodialysis patients with ischemic heart disease, the effects
of PCI versus medical therapy were studied.6 Both cardiac
and all-cause death were significantly lower in the PCI group,
regardless of the number of diseased vessels.
Although coronary angiography remains the gold stan-
dard, its high cost and potential adverse effects on residual
renal function advocate the search for an adequate non-
invasive screening test. A number of noninvasive techniques
are available, but none of these has proved to be both
practical and reliable in the hemodialysis population.
Myocardial perfusion scintigraphy (MPS), with dipyridamole
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to increase coronary flow, has been used as an alternative to
exercise. Dipyridamole induces arteriolar vasodilation
through inhibition of adenosine breakdown and inhibition
of cellular uptake. Several studies have reported an increased
relative risk for cardiac events in patients with abnormal
versus those with normal test results.7–13 Some of the studies
that sought to validate dipyridamole MPS against coronary
angiography, however, reported exceedingly low sensitiv-
ity.14,15 The disappointing results have been attributed to
abnormally high resting levels of adenosine in ESRD,
resulting in a blunted vasodilatory response14 or an altered
vascular reactivity owing to diabetes15,16 or left ventricular
hypertrophy,15 and the use of dipyridamole MPS has been
considered to be unreliable in ESRD. Dobutamine is
frequently used as an alternative pharmacological stressor,
often in conjunction with echocardiography.17 Dobutamine
increases myocardial oxygen consumption by sympathetic
stimulation, resulting in increased heart rate and contrac-
tility. The increased oxygen demand results in a secondary
dilation of the coronary arteries. In addition, dobutamine has
a minor direct vasodilatory effect on coronary vessels. In view
of this mechanism of action, dobutamine MPS may be a
more accurate predictor of CAD in hemodialysis patients.
However, no direct comparisons with dipyridamole MPS
have been reported in a hemodialysis population.
The present prospective study was therefore designed to
make a head-to-head comparison of dipyridamole and
dobutamine as cardiac stressors for MPS in patients on
chronic hemodialysis. The ability of these two stressors to
identify patients at risk for the subsequent development of a
fatal or non-fatal cardiac event was studied. In addition, we
assessed side effects and subjective tolerability.
RESULTS
Characteristics and tolerability of MPS
A total of 121 patients were enrolled and scheduled to
undergo resting MPS, dipyridamole MPS, and dobutamine
MPS. Ten patients eventually underwent no dobutamine
MPS and one patient had no rest study, because of either
logistic constraints or clinical problems. The quality of
perfusion images was deemed insufficient in 3/120 rest MPS,
6/121 dipyridamole MPS, and 5/111 dobutamine MPS (NS).
The left ventricular ejection fraction (LVEF) was judged
unreliable in 5/120 rest MPS, 10/121 dipyridamole MPS, and
in 8/111 dobutamine MPS (NS). As a left bundle branch
block may induce false-positive septal perfusion defects in
dobutamine rather than in dipyridamole MPS, we decided to
exclude five patients who had a left bundle branch block at
inclusion. The baseline characteristics of 102 patients who
entered the final analysis are summarized in Table 1.
Heart rate and blood pressure before starting were not
different for dipyridamole and dobutamine MPS (Table 2).
Despite specific instructions to withdraw b-blocking agents
and the use of atropine in addition to dobutamine, more
than one-third of patients did not achieve the target heart
rate (85% of maximum) during dobutamine infusion
(Table 2). Significantly more patients developed electrocar-
diographic signs of ischemia and arrhythmia during the
dobutamine test than during dipyridamole infusion. Dobu-
tamine infusion was interrupted in one patient due to severe
chest pain. The scoring of subjective discomfort was not
significantly different between both stressors (Table 2).
LVEF was significantly lower at dobutamine MPS than at
dipyridamole MPS (Table 3). Although a comparable
number of irreversible lesions were observed, more reversible
lesions were seen during dobutamine MPS. These were also
larger and/or more marked, reflecting in the summed
difference and summed stress scores being significantly
higher with dobutamine MPS. As a result, the subgroup of
patients with both normal functional and perfusion results
was significantly smaller at dobutamine compared with
dipyridamole MPS.
In 43 of the 97 patients evaluated, the semi-quantitative
analysis was identical for dobutamine and dipyridamole stress
studies. In 18 patients, one of the stress studies was normal,
whereas the other was abnormal: dipyridamole normal and
dobutamine reversible defects (n¼ 14), dipyridamole rever-
sible defects and dobutamine normal (n¼ 3), or dipyridamole
irreversible defect and dobutamine normal (n¼ 1). In the
remaining 36 patients, different perfusion defects were de-
tected in both studies: in the same vascular territories
Table 1 | Baseline characteristics of the study population
(N=102)
Mean (s.d.) or % (n)
Age (years) 64.3 (10.8)
Male sex (%) 59.8% (61/102)
Dialysis vintage (number of years in dialysis)a 0.89 (0.32–2.42)
Cardiovascular history
Acute myocardial infarction (%) 7.8% (8/102)
Percutaneous coronary intervention (%) 8.8% (9/102)
Coronary artery bypass grafting (%) 15.7% (16/102)
Cerebrovascular disease (%) 27.4% (28/102)
Peripheral vascular disease (%) 21.6% (22/102)
History of cardiovascular disease (%) 50.0% (51/102)
History of coronary artery disease (%) 22.6% (23/102)
Cardiovascular risk factors
Positive familial history (%) 14.8% (13/88)
Hypertension (%) 80.4% (82/102)
Hypercholesterolemia (%) 51.0% (52/102)
Diabetes (%) 32.4% (33/102)
Current smoking (%) 11.8% (12/102)
Clinical characteristics
Body mass index (kg/m2) 26.2 (4.4)
Predialysis systolic pressure (mmHg) 145.8 (20.3)
Predialysis diastolic pressure (mmHg) 77.2 (11.2)
Baseline ECG alterations
Supraventricular arrhythmias (%) 3.9% (4/102)
Left ventricular hypertrophy
Present (%) 66.3% (59/89)
Left ventricular mass index (g/m2) 135.6 (48.0)
ECG, electrocardiogram.
aMedian (interquartile range).
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(n¼ 29), an additional territory with dipyridamole (n¼ 3),
an additional territory with dobutamine (n¼ 3), or in dif-
ferent territories (n¼ 1). Figure 1 details the distribution of
reversible perfusion defects over the 17 myocardial segments.
Reversible perfusion defects occurred significantly more fre-
quent in the anteroseptal segments in the dobutamine tests.
Diagnostic accuracy
In the patients who underwent a prospectively scheduled
coronary angiography independently of the results of
MPS, sensitivity, specificity, and accuracy for detection of
significant stenoses were 57, 59, and 58% for dipyridamole,
and 57, 24% (P¼ 0.03 vs dipyridamole), and 39% (P¼ 0.03
vs dipyridamole) for dobutamine.
Prognostic power
Patients were prospectively followed up for 4.4 years on an
average. Kidney or combined kidney–pancreas transplanta-
tion was performed in 30 and 2 patients, respectively, but the
recording of end points continued uninterrupted. Forty-three
Table 2 | Characteristics of dobutamine and dipyridamole stress testing
Mean (s.d.) or % (n) Dobutamine Dipyridamole Significancea
Heart rate rest (beats/min) 76.6 (13.7) 77.8 (17.2) P=0.39
Systolic blood pressure rest (mmHg) 151.4 (30.7) 150.5 (29.2) P=0.77
Diastolic blood pressure rest (mmHg) 78.5 (16.7) 79.4 (15.6) P=0.38
Heart rate peak (beats/min) 132.8 (15.7) — —
Systolic blood pressure peak (mmHg) 169.6 (37.8) — —
Diastolic blood pressure peak (mmHg) 75.8 (16.7) — —
Heart rate achieved (% maximum) 85.6 (10.3) — —
Heart rate achieved o85% maximum 44.3% (43/97) — —
Ischemia on ECG (%) 20.6% (21/102) 7.8% (8/102) P=0.0008
Angina (%) 8.9% (9/101) 6.9% (7/101) P=0.56
Arrhythmia (%) 28.4% (29/102) 15.7% (16/102) P=0.009
Subjective score (scale 0–10)b 1 (0–3) 1 (0–2) P=0.19
ECG, electrocardiogram.
aAccording to the Wilcoxon’s signed-rank test or the McNemar’s test.
bMedian (interquartile range).
Table 3 | Characteristics of MPS
Rest
LVEF, mean (s.d.) 54.4 (14.1)
LVEF o45%, % (n) 22.2% (22/99)
Summed rest score: mean, median (IRa) 2.31, 1 (0–4)
Categories, % (n): 0 50.5% (51/101)
1–3 20.8% (21/101)
X4 28.7% (29/101)
Stress Dipyridamole Dobutamine P-valueb
LVEF, mean (s.d.) 57.6 (13.0) 53.9 (12.4) Po0.0001
o45% 16.0% (15/94) 21.3% (20/94) P=0.06
Global perfusion result, % (n)c
N 41.8% (41/98) 31.6% (31/98)
R 16.3% (16/98) 28.6% (28/98) ‘R or I or R/I’ vs ‘N’: P=0.02
I 23.5% (23/98) 19.4% (19/98) ‘R or R/I’ vs ‘N’: P=0.008
R/I 18.4% (18/98) 20.4% (20/98) ‘I or R/I’ vs ‘N’: P=0.48
Summed stress score: mean, median (IRa) 3.88, 1 (0–5) 4.42, 2 (0–6) P=0.009
Categories, % (n): 0 41.4% (41/99) 31.3% (31/99)
1–3 25.2% (25/99) 26.3% (26/99)
X4 33.3% (33/99) 42.4% (42/99)
Summed difference score: mean, median (IRa) 1.63, 0 (0–2) 2.11, 0 (0–3) P=0.02
Categories, %(n): 0 65.3% (64/98) 51.0% (50/98)
1–3 17.4% (17/98) 26.5% (26/98)
X4 17.4% (17/98) 22.4% (22/98)
SDS X4 or LVEF o45%, % (n) 26.9% (25/93) 37.6% (35/93) P=0.02
LVEF, left ventricular ejection fraction; SDS, summed difference score.
aIR=interquartile range.
bAccording to the Wilcoxon’s signed-rank test or the McNemar’s test.
cN=normal perfusion; R=presence of reversible defect; I=presence of irreversible defect; R/I=presence of both reversible and irreversible defects.
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patients (42%) died during follow-up, 11 of which were due
to CAD (six fatal acute myocardial infarctions and five heart
failure). Sudden death occurred in four patients. In addition,
28 patients (26%) developed non-fatal CAD (three had non-
fatal acute myocardial infarction, eight were hospitalized for
heart failure, 25 underwent CABG, PCI, or additional
medical treatment for a documented coronary stenosis, and
three had non-fatal arrhythmia). This resulted in a total CAD
incidence of 143 per 1000 person-years.
Low LVEF at rest (o45%) was an independent predictor
of total mortality, CAD mortality, and fatal and non-fatal
CAD (Tables 4–6). Most functional parameters were strongly
related to fatal and non-fatal CAD for dipyridamole MPS,
but not for dobutamine MPS. For dipyridamole MPS, the
hazard ratios for CAD death associated with a high (X4)
summed stress score (SSS) and summed difference score
(SDS) were 5.48 and 7.16, respectively. For both dobutamine
and dipyridamole MPS, the presence of an irreversible defect
in the absence of a reversible defect was not predictive of
future events, even when only large defects were considered
(SRS X4).
The better distinction by dipyridamole MPS than by
dobutamine MPS of patients at high versus low risk is
graphically illustrated in the Kaplan–Meier curves (Figure 2
for CAD mortality and Figure 3 for all CAD-related events).
Patients with pronounced ischemia on dipyridamole MPS
(SDS X4) have a shorter time course to a fatal CAD event
(Figure 2a) and a shorter survival free of CAD-related events
(Figure 3a) than those without pronounced ischemia on
dipyridamole MPS. In contrast, patients with a comparable
degree of ischemia on dobutamine MPS (SDS X4) do not
seem to fare worse than those without such ischemia on
dobutamine MPS (Figures 2b and 3b).
The 2-year CAD-free survival in patients with normal-
stress MPS, defined as MPS not showing reversibility and an
LVEF of at least 45%, was 84.6% for dipyridamole and 85.6%
for dobutamine.
An additional analysis was performed to evaluate a
potential confounding effect of left ventricular hypertrophy
on the occurrence of reversible lesions during MPS. When
differential ischemia between dobutamine and dipyridamole
MPS, as measured by the difference of the corresponding
SDS, was compared in three tertiles of the left ventricular
mass index, no trend of an increased difference between
dobutamine and dipyridamole MPS for a higher left
ventricular mass was observed.
The relative likelihood of undergoing PCI or CABG within
2 months after MPS in the group with SDS X4 versus that
with SDS o4 was 4.34 (1.66–11.31) for dipyridamole and
2.06 (0.74–5.70) for dobutamine.
DISCUSSION
This study was designed to determine whether either
dobutamine or dipyridamole is the optimal cardiac stressor
in a hemodialysis population, with respect to tolerability and
prognostic power.
Both dobutamine and dipyridamole have been reported to
be generally well tolerated in a hemodialysis population,18,19
but no direct comparisons are available. The chronotropic
incompetence that contributes to submaximal exercise testing
in hemodialysis patients was also evident during dobutamine
testing. More than one-third of patients failed to achieve the
target heart rate (85% of maximum) during dobutamine
infusion, which is in agreement with previous reports.20
Nevertheless, more patients developed ischemic changes on
ECG or experienced arrhythmias during dobutamine infu-
sion than during dipyridamole stress. Dobutamine stress also
induced more, larger, and more intense reversible perfusion
defects than did dipyridamole infusion. Despite these
differences, subjective tolerance was similar for both
pharmacological agents. This may be in keeping with the
high prevalence of asymptomatic CAD in current hemodia-
lysis populations.
The diagnostic accuracy of both stressors was studied in a
subset of patients in whom coronary angiography was
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Figure 1 |Bull’s eye representation of segments with
reversible defects in 97 patients. *P¼ 0.04 versus dipyridamole
by McNemar’s test; **P¼ 0.01 versus dipyridamole by McNemar’s
test.
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performed subsequent to the MPS studies. To avoid selection
bias, only those patients who were designated to undergo
coronary angiography independently of the result of MPS
were included in the analysis. Although sensitivity was
similar, specificity was markedly lower for dobutamine
than for dipyridamole. Multiple factors intervene between
stenosis of the epicardial coronary arteries, as visualized on
coronary angiography, and diminished blood flow, as
visualized on MPS. These include the functional severity of
stenosis, the presence of a collateral circulation, as well as the
status of the distal vascular bed and the microcirculation.
Coronary angiography may therefore not be the best
standard to assess MPS. The ability to predict CAD-related
events may be a more relevant criterion to judge non-invasive
tests.
The novel observation of this study is that myocardial
perfusion defects revealed by dipyridamole stress are stronger
multivariate predictors of fatal and non-fatal CAD in chronic
hemodialysis patients than defects induced by dobutamine
infusion. Reversible defects on dobutamine MPS, although
being more numerous and more marked, do not convey a
significant risk for future events. In agreement with previous
studies of dipyridamole MPS,12,21 we found that only
reversible and not fixed defects independently predict fatal
and non-fatal CAD. Using stepwise logistic regression
analysis, Brown et al.8 found that only irreversible defects
Table 4 | Prognostic value of functional and perfusion parameters: total mortality
Rest
HR (95% CI)a v2 P
LVEF o45% 3.35 (1.74–6.48) 12.98 P=0.0003
SRS: 1–3 vs 0 1.57 (0.60–4.08) 0.85 P=0.36
SRS: X4 vs 0 2.00 (0.77–5.20) 2.01 P=0.16
Dipyridamole Dobutamine
HR (95% CI)a v2 P HR (95% CI)a v2 P
LVEF o45% 2.07 (0.88–4.89) 2.78 P=0.10 1.81 (0.81–4.04) 2.08 P=0.15
R or I or R/I vs Nb 1.67 (0.82–3.41) 1.99 P=0.16 0.85 (0.40–1.80) 0.18 P=0.68
R vs N 1.99 (0.86–4.60) 2.61 P=0.11 0.39 (0.14–1.08) 3.27 P=0.07
I vs N 1.25 (0.40–3.94) 0.15 P=0.70 0.69 (0.22–2.16) 0.41 P=0.52
SSS: 1–3 vs 0 1.40 (0.61–3.20) 0.62 P=0.43 0.71 (0.29–1.75) 0.55 P=0.46
SSS: X4 vs 0 2.08 (0.86–5.01) 2.67 P=0.10 1.00 (0.42–2.35) 0.01 P=0.99
SDS: 1–3 vs 0 1.16 (0.47–2.89) 0.11 P=0.74 0.52 (0.22–1.26) 2.09 P=0.15
SDS: X4 vs 0 2.20 (0.99–4.89) 3.71 P=0.06 1.03 (0.48–2.23) 0.01 P=0.94
SDS 4 or LVEFo45% 2.00 (0.98–4.10) 3.60 P=0.06 1.65 (0.87–3.16) 2.32 P=0.13
CAD, coronary artery disease; LVEF, left ventricular ejection fraction; SDS, summed difference score; SRS, summed rest score; SSS, summed stress score.
aHazard ratios (95% CI) adjusted for age, sex, history of CAD, diabetes, hypertension and center (Cox proportional hazards regression analysis).
bN=normal perfusion; R=presence of reversible defect; I=presence of irreversible defect; R/I=presence of both reversible and irreversible defects.
Table 5 | Prognostic value of functional and perfusion parameters: CAD mortality
Rest
HR (95% CI)a v2 P-value
LVEF o45% 7.13 (2.02–25.15) 9.32 P=0.002
SRS: 1–3 vs 0 3.02 (0.44–20.86) 1.26 P=0.26
SRS: X4 vs 0 7.93 (1.04–60.50) 3.99 P=0.04
Dipyridamole Dobutamine
HR (95% CI)a v2 P-value HR (95% CI)a v2 P-value
LVEF o45% 3.50 (0.94–13.05) 3.47 P=0.06 3.10 (0.87–11.07) 3.02 P=0.08
R or I or R/I vs Nb 3.28 (0.81–13.23) 2.78 P=0.10 2.25 (0.54–9.32) 1.25 P=0.26
R vs N 14.68 (1.87–115.30) 6.52 P=0.01 1.65 (0.23–11.61) 0.25 P=0.62
I vs N 0.74 (0.02–25.39) 0.03 P=0.87 2.51 (0.13–48.88) 0.37 P=0.54
SSS: 1–3 vs 0 1.77 (0.29–10.96) 0.38 P=0.54 1.92 (0.37–9.98) 0.60 P=0.44
SSS: X4 vs 0 5.48 (1.12–26.85) 4.40 P=0.04 2.67 (0.52–13.63) 1.39 P=0.24
SDS: 1–3 vs 0 1.12 (0.12–10.52) 0.01 P=0.92 1.38 (0.29–6.52) 0.17 P=0.68
SDS: X4 vs 0 7.16 (1.80–28.55) 7.78 P=0.005 1.64 (0.38–7.17) 0.44 P=0.51
SDS X4 or LVEFo45% 5.20 (1.37–19.75) 5.87 P=0.02 2.43 (0.73–8.12) 2.08 P=0.04
CAD, coronary artery disease; LVEF, left ventricular ejection fraction; SDS, summed difference score; SRS, summed rest score; SSS, summed stress score.
aHazard ratios (95% CI) adjusted for age, sex, history of CAD, diabetes, hypertension and center (Cox proportional hazards regression analysis).
bN=normal perfusion; R=presence of reversible defect; I=presence of irreversible defect; R/I=presence of both reversible and irreversible defects.
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on thallium MPS and left ventricular dysfunction on
radionuclide ventriculography were independent predictors.
In contrast, other authors reported that both reversible and
fixed defects were prognostic of cardiac events.22,23
We can only speculate with regard to the causes of the
better predictive ability of dipyridamole versus that of
dobutamine. It remains to be seen whether it would hold
when echocardiography, instead of MPS, would be used with
one or both of the stressors. In this respect, it should be
emphasized that the detection of ischemia by echocardio-
graphy relies on the induction of wall motion abnormalities,
whereas MPS measures myocardial perfusion in a more direct
way. It is known that the presence of a left bundle branch
block may be associated with false-positive septal perfusion
defects with dobutamine rather than with dipyridamole
MPS. A large proportion of patients with left bundle branch
block may thus skew the results to the disadvantage of
dobutamine. We therefore have excluded five patients with a
left bundle branch block from the final analysis to eliminate
this possibility. We suspect that the chronotropic action of
high-dose dobutamine, albeit somewhat blunted in the
dialysis population, may induce alterations of wall motion
that may lead to spurious perfusion defects, similar to the
artifacts seen with left bundle branch block. An argument in
favor of this hypothesis is that the higher number of
reversible defects with dobutamine in our study can be
largely attributed to the anteroseptal wall, similar to the left
bundle branch block artifacts. Our data do not support the
hypothesis that left ventricular hypertrophy is a major
determinant of the enhanced ischemia seen with dobutamine
versus dipyridamole, because we did not observe an increased
difference between dobutamine and dipyridamole MPS in
those patients with the highest left ventricular mass. Finally, it
should be emphasized that we used a higher dose of
dipyridamole than in all previous studies of dipyridamole
MPS in ESRD. It is unclear whether this may have influenced
the results substantially.
Dipyridamole MPS provides information incremental to
clinical data and accurately identifies patients at increased odds
for fatal and non-fatal CAD-related events, who therefore need
more aggressive treatment. Conversely, an optimal risk
stratification discriminates patients who do not require further
intervention. A normal dipyridamole MPS was associated with
a 2-year CAD-free survival of 85%. Re-testing of patients with
normal studies every 2–3 years thus seems to be a reasonable
strategy. However, the risk for CAD-related events despite a
normal MPS remains much higher in patients with ESRD than
that in the general population. ESRD is a powerful modifier of
the prognostic value of a normal MPS.24 Clinical suspicion
should therefore continue to be high.
A limitation of the study is that clinicians were not
blinded to the results of MPS that was performed as part of
the study, because this was considered unethical. They were
free to use the information gained to define the therapeutic
strategy deemed optimal. A positive MPS may have led to a
coronary angiography and a subsequent revascularization
procedure, and may therefore have introduced a detection
bias. We have partly corrected for this bias by censoring
events occurring within 2 months of MPS. It has been
demonstrated that coronary revascularization reduces the
risk of coronary events in chronic hemodialysis patients.5,6
The execution of an MPS may thus have decreased the risk at
further events. Therefore, all relative risks obtained should be
regarded as conservative estimates. It could be argued that
the larger number of reversible lesions revealed by dobuta-
mine led to a higher number of revascularization procedures,
with a subsequent protection of these patients from further
events. This mechanism would then falsely make dobutamine
seem less predictive of CAD. However, the relative likelihood
of undergoing a PCI or CABG within 2 months of MPS in
Table 6 | Prognostic value of functional and perfusion parameters: CAD
Rest
HR (95% CI)a v2 P-value
LVEF o45% 2.03 (0.97–4.25) 3.54 P=0.06
SRS: 1–3 vs 0 0.91 (0.31–2.68) 0.03 P=0.86
SRS: X4 vs 0 3.14 (1.21–8.13) 5.56 P=0.02
Dipyridamole Dobutamine
HR (95% CI)a v2 P-value HR (95% CI)a v2 P-value
LVEF o45% 1.96 (0.84–4.62) 2.40 P=0.12 2.20 (1.02–4.70) 4.09 P=0.04
R or I or R/I vs Nb 2.14 (1.02–4.51) 4.01 P=0.04 1.48 (0.67–3.28) 0.94 P=0.33
R vs N 3.16 (1.20–8.36) 5.41 P=0.02 1.19 (0.43–3.26) 0.11 P=0.74
I vs N 1.27 (0.35–4.60) 0.13 P=0.72 1.12 (0.24–5.12) 0.02 P=0.88
SSS: 1–3 vs 0 1.21 (0.46–3.16) 0.15 P=0.70 1.10 (0.41–2.94) 0.04 P=0.84
SSS: X4 vs 0 2.90 (1.25–6.75) 6.11 P=0.01 1.82 (0.74–4.48) 1.71 P=0.19
SDS: 1–3 vs 0 1.08 (0.40–2.94) 0.02 P=0.88 1.94 (0.88–4.26) 2.74 P=0.10
SDS: X4 vs 0 3.66 (1.69–7.91) 10.86 P=0.001 1.57 (0.63–3.89) 0.95 P=0.33
SDS X4 or LVEFo45% 2.60 (1.25–5.41) 6.54 P=0.01 2.08 (1.02–4.22) 4.10 P=0.04
CAD, coronary artery disease; LVEF, left ventricular ejection fraction; SDS, summed difference score; SRS, summed rest scores; SSS, summed stress score.
aHazard ratios (95% CI) adjusted for age, sex, history of CAD, diabetes, hypertension, and center (Cox proportional hazards regression analysis).
bN=normal perfusion; R=presence of reversible defect; I=presence of irreversible defect; R/I=presence of both reversible and irreversible defects.
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patients with SDS X4 versus those with SDS o4 actually
tended to be higher with dipyridamole than with dobuta-
mine, which excludes this possibility.
In conclusion, we found that in hemodialysis patients, a
high-dose dipyridamole MPS is a better predictor for future
CAD-related events than is dobutamine MPS. Dipyridamole
should be the preferred cardiac stressor in the noninvasive
screening of ESRD patients for CAD.
METHODS
Study population
The study was conducted at two tertiary care hospitals in the Belgian
cities of Bruges and Ghent. All patients aged more than 18 years and
in chronic hemodialysis for more than 1 month were eligible, except
those with recent (o3 months) myocardial infarction or revascu-
larization. Exclusion criteria were pregnancy, breastfeeding, and
contraindications to dipyridamole (unstable angina, severe chronic
obstructive pulmonary disease or asthma, treatment with methyl-
xanthines, predialysis systolic blood pressure below 90mmHg) or
dobutamine (unstable angina, severe aortic stenosis, hypertrophic
obstructive cardiomyopathy, atrial tachyarrhythmia with uncon-
trolled ventricular response, ventricular tachycardia, predialysis
blood pressure of more than 200/100mmHg, aortic dissection
and large aortic aneurysm) administration. All patients who fulfilled
the inclusion and exclusion criteria and provided informed consent
were included. At inclusion, a full medical history, including risk
factors for coronary artery disease, was recorded. Positive familial
history was defined as a first-degree relative with premature
cardiovascular disease.
Physical examination was performed and a blood sample was
taken for risk factor determination. Hypertension was defined as
X140mmHg systolic and/or X90mmHg diastolic pressure on
more than one occasion and/or antihypertensive drug treatment.
Diabetes mellitus was diagnosed according to the World Health
Organization criteria. Hypercholesterolemia was defined as plasma
total cholesterol 4190mg/100ml and/or treatment with cholesterol-
lowering drugs. An ECG and a chest X-ray were performed.
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Figure 2 |Kaplan–Meier survival curves for patients who had a
summed difference score o4 (solid line) or X4 (dashed line)
at myocardial perfusion scintigraphy, with dipyridamole
(a) or dobutamine (b). CAD, coronary artery disease.
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Figure 3 |Kaplan–Meier curves for freedom from fatal or non-
fatal CAD events in patients who had a summed difference
score o4 (solid line) or X4 (dashed line) at myocardial
perfusion scintigraphy, with dipyridamole (a) or
dobutamine (b). CAD, coronary artery disease.
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A two-dimensionally guided M-mode echocardiographic study
was carried out in resting conditions for atrial and left ventricular
measurements, including interventricular septal thickness at
end-diastole (IVSTd), left ventricular internal dimension at end-
diastole (LVIDd), and posterior wall thickness at end-diastole
(PWTd). Measurements were made in accordance with the
recommendations of the American Society of Echocardio-
graphy. Left ventricular mass (g) was calculated using the
formula 0.80 [1.04 (IVSTdþ LVSTdþPWTd)3LVIDd3]þ 0.6 g.
Left ventricular mass index was derived by dividing the left
ventricular mass by body surface area. Left ventricular mass index
4116 g/m2 in men and 4104 g/m2 in women was the criterion for
left ventricular hypertrophy. The study protocol was approved by
the Institutional Review Board at both institutions involved. All
patients gave written informed consent.
Myocardial perfusion scintigraphy
Patients were scheduled to undergo three MPS on separate days, but
within a 3-week period: at rest, after dipyridamole infusion, and
after dobutamine infusion. The order of the tests was determined by
logistic considerations. b-blockers were withdrawn 24 h before MPS.
Phylline-containing drugs, beverages or foods were prohibited 24 h
before dipyridamole MPS. Patients were fasting for at least 4 h. MPS
was always performed on a midweek dialysis day, after the dialysis
session.
Dobutamine was infused at a dose of 10mg/kg per min, with
10mg/kg per min increments at 3min intervals, up to a maximal rate
of 40mg/kg per min. Atropine (4 0.25mg at 1min intervals) was
allowed to achieve the target heart rate. 99mTc-Sestamibi was
administered at a dose of 925MBq when at least 85% of the
predicted maximal heart rate (220–patient’s age) was achieved.
Dobutamine infusion was continued for 2min after administration
of the perfusion tracer. Dipyridamole was infused at a dose of
0.84mg/kg over 6min. 99mTc-Sestamibi was administered at a dose of
925MBq 2 upto 5min after completion of the dipyridamole infusion.
After MPS, patients were asked to score subjective discomfort
caused by dipyridamole or dobutamine on a visual analog scale
(0–10).
Acquisition was started at least one-half hour after tracer
administration for stress studies and 45min for rest studies.
Imaging was performed using a three-headed g camera (Multi-
spect3, Siemens, Erlangen, Germany at Bruges; Prism3000, Marconi,
Picker, Cleveland, Ohio at Ghent) fitted with low energy collimators.
The patients were in supine position, if possible with the arms out of
the field of view. Images were acquired from 96 (Bruges) to 120
(Ghent) detector positions over a 360-degree noncircular contour.
The dwell time on each position was 40 to 20 s, respectively. The
energy window was 15%, centered around 141 keV. The matrix size
was 64 64, with the original pixel size being 7.12mm on the
Siemens Multispect and 5.01mm on the Picker Prism; a zoom factor
of 1.23 was used on the Siemens system to obtain a pixel size of
5.79mm. Gated images were acquired into eight time bins. The
gating window center was set manually.
Images were reconstructed using a Butterworth filter (cutoff 0.35
cycles/cm, order 5). The volume was reoriented along the long axis.
This was carried out by one observer (PF) for the three imaging sets
together, in order to align the datasets as good as possible. The
perfusion images as well as the functional parameters derived from
the gated study were judged as adequate or inadequate. Stress/rest
couples were presented to the readers in a random order so as to
blind the readers to the result of the other stress study for the same
patient and to the nature of the stressor used in a particular study.
Three experienced nuclear physicians, also blinded to the clinical
data, scored myocardial perfusion on the ungated image sets, by
consensus and using a 17-segment ventricular model and a semi-
quantitative scoring system from 0 to 4: 0¼ normal tracer
accumulation, 1¼mild defect, 2¼moderate defect, 3¼ severe
defect, 4¼ absent perfusion. Stress myocardial perfusion scintigra-
phies were categorized as ‘normal’ when all segments were scored as
0, as ‘reversible’ if any segmental score of 1 or higher at stress
decreased at the rest study, or as ‘irreversible’ if none of the
abnormal segmental scores at stress decreased at the rest study. The
use of gated images was limited to the differentiation between
attenuation defects and fixed real perfusion defects. Summed stress
scores, summed rest scores (SRS), and reversibility scores (summed
difference scores, SDS) were calculated as the sums of all segmental
scores in each of the myocardial segments. LVEF was calculated
using Quantitative Gated SPECT software version 4.0, commercially
obtained from the camera vendors.
Coronary angiography
Patients with stable angina and patients evaluated for kidney
transplantation (n¼ 35) were prospectively designated to undergo
coronary angiography, independently from the result of MPS.
Coronary angiography and left ventriculography were performed
using a standard approach with six French catheters. Ventriculo-
graphy was performed in the 301 right anterior oblique and 601
left anterior oblique views. Coronary arteries were selectively
injected in multiple views. End-diastolic cine frames were selected
for optimal stenosis visualization. Stenoses were evaluated in two
orthogonal views. A normal arterial segment was identified
immediately proximal and distal to the lesion and measured with
an electronic caliper. The minimal stenosis diameter was also
measured and severity was expressed as percent reduction of the
normal diameter. Significant CAD was considered present in the
case of a reduction of 70% or more in the luminal diameter of at
least one major epicardial vessel or 50% or more in the left main
coronary. Coronary angiography was performed on an average of 46
days (s.d. 31 days, median 37 days) after inclusion. Two patients
were excluded from the analysis because of intercurrent clinical
problems in the interval between coronary angiography and MPS.
Two additional patients were excluded owing to the presence of a left
bundle branch block on the baseline ECG. For the comparison of
MPS results with those of coronary angiography, MPS was
considered abnormal when any reversible or irreversible defect was
detected.
Patient follow-up
After enrollment, patients were followed up 3-monthly, on the
basis of medical history, physical examination, and blood tests.
Six-monthly ECGs and chest X-rays were taken and echocardio-
graphy was repeated every year. End points were recorded at each
visit.
Fatal end points were all-cause mortality and CAD mortality.
CAD mortality included death due to cardiac arrhythmia, congestive
heart failure, or myocardial infarction. Sudden death was recorded
separately and not included in the analysis of CAD mortality, to
avoid confounding by cardiac arrest due to hyperkalemia in the
absence of structural heart disease. Non-fatal CAD included the
following:
K Non-fatal acute myocardial infarction, documented by at least
two of the following: a clinical history suggesting acute
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myocardial infarction, ECG changes suggestive of myocardial
infarction, and a significant rise of myocardial enzymes
(according to WHO criteria issued in 1995).
K New or increasing angina (new-onset exertional angina,
accelerated or rest angina, or both) requiring upgrading of
medical therapy, treatment by PCI or CABG.
K Angiographic findings of one or more epicardial vessel
stenosis of at least 70% or of at least 50% in the left main
coronary, which were treated by PCI or CABG. If a coronary
arteriography had been performed before enrollment, only new
lesions were taken into account.
K Hospitalization for congestive heart failure, defined as the
presence of symptoms or signs of left or right heart failure such
as auscultatory rales or peripheral edema, in the presence of
documented ventricular dysfunction. Fluid overload due to
inadequate adjustment of dry weight was not considered to be
an end point.
K New-onset ventricular or supraventricular arrhythmias result-
ing in hemodynamic compromise.
The physicians of the dialysis units were not blinded to the results of
MPS. To avoid confounding introduced by the performance of
coronary angiography after MPS, non-fatal end points occurring
within 2 months of enrollment were censored from the analysis.
Statistical analysis
The distributions of study variables were characterized according to
means, s.d., medians, interquartile ranges, and proportions.
Differences in the characteristics of dipyridamole MPS and
dobutamine MPS were evaluated using Wilcoxon’s signed rank test
for quantitative variables or McNemar’s test for dichotomous
variables. Differences in differential ischemia of dobutamine versus
dipyridamole MPS, according to the degree of left ventricular
hypertrophy, were assessed using the Kruskal–Wallis test. The
estimation of CAD-free survival in patients with normal dipyr-
idamole MPS was carried out according to the Kaplan–Meier
method.25 Hazard ratios and their 95% confidence intervals were
estimated according to Cox proportional hazard modeling, with age,
sex, history of CAD, diabetes, hypertension, and recruitment center
as covariates.25 The model assumption of proportionality of hazards
was checked by plotting log [log(S(t))] against time, where S(t)
represents the Kaplan–Meier survival estimate.25 P-values were
obtained through Wald w2 statistics. All statistical analyses were
performed using SAS software (The SAS system, Release 9.1.3, Cary,
NC, USA: SAS Institute Inc.).
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